Summary & Overview
HCPCS P9026: Cryoprecipitated Fibrinogen Complex, Pathogen Reduced, Each Unit
HCPCS Level II code P9026 represents a unit of pathogen-reduced cryoprecipitated fibrinogen complex, a concentrated plasma-derived product used to replace fibrinogen and support hemostasis in patients with fibrinogen deficiency. Nationally, availability and billing for pathogen-reduced blood products are important as hospitals and transfusion services adopt enhanced pathogen mitigation processes and integrate newer product types into clinical workflows. Major payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn what P9026 denotes clinically, the common settings where it is administered (hospital inpatient transfusion services and outpatient infusion/transfusion centers), and the typical service classification as a blood product/transfusion support item. The publication provides benchmark-oriented content and policy-relevant context such as payer coverage patterns, coding considerations, and where to look for updates on product handling and billing practices. Data not available in the input will be noted where applicable; the focus remains on clarifying the clinical purpose of the code and the payer landscape relevant to national billing and coverage discussions.
Billing Code Overview
HCPCS Level II code P9026 describes cryoprecipitated fibrinogen complex, pathogen reduced, each unit. This item is a plasma-derived blood product prepared to provide concentrated fibrinogen and other clotting factors for patients with hypofibrinogenemia or acquired fibrinogen deficiency.
-
Service type: Blood product / transfusion support
-
Typical site of service: Hospital inpatient or outpatient infusion/transfusion center
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with decompensated liver cirrhosis is admitted to an inpatient hematology service for acute gastrointestinal bleeding and develops clinically significant hypofibrinogenemia with poor hemostasis. After laboratory testing shows fibrinogen concentration <100 mg/dL and persistent oozing at the endoscopy site, the transfusion medicine team orders cryoprecipitated fibrinogen complex for hemostatic support. A unit of P9026 (cryoprecipitated fibrinogen complex, pathogen reduced, each unit) is issued from the hospital blood bank. The product is administered in an acute care setting (inpatient ward, operating room, or interventional radiology) by nursing staff under transfusion protocols, with pretransfusion compatibility checks, baseline vital signs, and posttransfusion monitoring for transfusion reactions. Documentation includes indication, unit number, volume infused, start and stop times, pre- and posttransfusion vitals, and any adverse events. Typical sites of service include the hospital inpatient unit, operating room, emergency department, and interventional radiology suite. Typical clinical reasons for use include acquired hypofibrinogenemia from liver disease, dilutional coagulopathy after massive transfusion, obstetric hemorrhage, or bleeding with low fibrinogen levels where fibrinogen concentrate is unavailable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier / Standard service |